

Metformin Is Not Associated with Incidence Risk of Non-Hodgkin Lymphomas among Diabetic Patients

Xibiao Ye^{1,2}, Geng Zhang^{1,2}, Christiaan Righolt^{1,2}, James B. Johnston^{4,5}, Versha Banerji^{4,5}, Spencer B. Gibson^{4,6,7}, Salaheddin M. Mahmud^{1,2,3}

¹Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada; ²Vaccine and Drug Evaluation Centre, University of Manitoba, Winnipeg, Manitoba, Canada; ³College of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada; ⁴Research Institute of Oncology and Hematology, CancerCare Manitoba, Canada; ⁵Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; ⁶Department of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada; ⁷Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada;

Running title: metformin use and non-Hodgkin lymphoma risk among diabetics

Keywords: non-Hodgkin lymphoma, metformin, cancer chemoprevention

Funding sources

Research reported in this publication was supported by Research Manitoba New Investigator Operating Grant awarded to X. Ye (#1286 YEX NI) and Research Manitoba CLL Research Cluster Grant awarded to S.B. Gibson (#761090863). The content is solely the responsibility of the authors and does not necessarily represent the official views of Research Manitoba.

Corresponding author:

Xibiao Ye, 333 Apotex Centre, 750 McDermot Avenue Winnipeg, Manitoba R3E 0T5

Email: xibiao.ye@gmail.com;

Tel: +1 (204) 782-6072; Fax: +1 (204) 947-9970

Conflict of interest statement

S.M.M. has received unrestricted research grants from GlaxoSmithKline, Merck, Sanofi Pasteur, Pfizer and Roche-Assurex for unrelated studies. J.B.J. and V.B. have received unrestricted research grants from Lundbeck, Gilead and Janssen Pharmaceuticals for unrelated projects and sit on advisory boards for Gilead, Janssen, and Abbvie Pharmaceuticals.

Abstract

Background: Several epidemiological studies have shown a positive association between diabetes and increased risk of non-Hodgkin lymphoma (NHL), but the effect of diabetic treatment drugs such as metformin on the risk is unknown.

Methods: We conducted a population-based nested case-control study involving 878 NHL cases and 4,364 controls diagnosed with diabetes. Use of metformin and other medications prior to diagnosis and medical condition histories were assessed using administrative databases. We used conditional logistic regression models to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for use of metformin, adjusting for confounders.

Results: Risk of total NHLs is not associated with ever use of metformin (OR=0.93 95% CI 0.79-1.10) among diabetic patients. NHL subtypes were also not associated with metformin use.

Conclusion: Metformin use is not associated with overall or subtype NHL risk among diabetic patients.

Impact: NHLs are etiologically heterogeneous and larger scale studies are warranted to test the potential effect of metformin by NHL subtype.

Introduction

Epidemiological studies have consistently shown associations between diabetes mellitus (DM) and an increased risk of some cancers (e.g., liver, pancreas, endometrium, colon and rectum, breast, bladder). (1) Potential preventative effects of antidiabetic drugs, such as metformin, on cancer have thus been hypothesized. Epidemiological evidence exists on the association between metformin and decreased incidence risk of overall and specific cancers (e.g., pancreatic and hepatocellular cancers) among diabetic patients. (2)

Immunosuppression, chronic inflammation, and lymphocyte dysfunction occurring in DM patients have been associated with the development of lymphoma, indicating a plausible link between DM and Non-Hodgkin lymphoma (NHL). (3) Several epidemiological studies have found that DM was associated with increased NHL incidence risk. (3,4) We have not found studies on the association between metformin and NHL. We aimed to study the association between metformin use and NHL risk in Manitoba, Canada.

Materials and methods

Data Sources

We conducted a population-based nested case-control study using cancer registry and health service administrative databases in Manitoba, Canada. The methods have been described in detail previously. Cases and controls were included if they were 40 years or older and had been diagnosed with diabetes (based on ICD-8/9 code 250.x and ICD-10 code E11-E14). Participants must have been registered with MH for no less than five years before the index date to be included in the study, to ensure that the histories of exposure, if any, are of adequate length. NHL cases were identified from the Manitoba Cancer Registry. For each case, five controls are matched on gender, age, region of residence, date of diabetes diagnosis, and length of registration with the provincial health insurance, using the risk set sampling approach. Case and control records were linked to prescription drug, hospital discharge, and physician claim databases. Medication use histories were ascertained for the period between the index date and April 1, 1995, or the coverage initiation date, whichever was later. Metformin use during the 1-year period prior to the index date was excluded to minimize protopathic bias – a drug can be used to target early disease symptoms.

We used conditional logistic regression models to calculate odds ratios (ORs) and 95% confidence intervals (CIs). The sample size ensured a greater than 80% statistical power to detect an OR between 0.6 and 1.5. We assessed potential confounders using the change-in-estimation method and clinical relevance. We adjusted for chronic cardiovascular diseases, use of statin and non-statin lipid-lowering drugs, aspirin, non-aspirin anti-steroidal anti-inflammatory drugs, income, and number of physician visits 5 years prior to diagnosis in the final analysis models. Separate analyses were undertaken for Total NHL and the main NHL subtypes including chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), plasma cell neoplasms (PCNs), follicular lymphoma (FL), and other NHLs. All data analysis was performed in Stata 14 (StataCorp LLC, College Station, Texas).

Results

In total 878 diabetic NHL cases were included. Cases and controls were similar in terms of demographics, medical condition and medication use histories, but cases tended to have more physician visits during the past five years prior to the index date (Table 1). About half of diabetes patients (cases and controls) were prescribed metformin. Approximately 16% and 49% of patients used insulin and other oral hypoglycemic drugs respectively. As shown in Table 2, metformin use was not associated with incidence risk of Total NHL (OR=0.93, 95% CI 0.79-1.10). There was also no associations between metformin use and incidence risk of NHL subtypes.

Discussion

We did not find an association between metformin use and NHL incidence risk among diabetic patients. A recent study reported an inverse association between metformin use and NHL risk among females, with an OR of 0.76 (95% CI 0.64–0.91).⁽⁵⁾ Unlike the present study, which is conducted among diabetic patients only, the recent study included all types of patients. Caution in interpreting the finding from the recent study is also warranted due to the lack of clarity for epidemiological methodology and the simultaneous testing of multiple hypotheses in the study.

Epidemiological studies demonstrated that diabetic patients treated with metformin had lower incidence or mortality risk for several cancers including colorectal, pancreatic, and hepatocellular cancers.⁽⁶⁾ Metformin has been associated with a reduced risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma.⁽⁷⁾ Metformin's anti-cancer mechanisms are unclear, but may involve multiple pathways including suppressing tumor cell growth via AMPK activation and inhibiting proliferation via the mTOR pathway. Those effects were demonstrated in lymphoma cells,⁽⁸⁾ indicating the biological possibility for metformin's effect in preventing lymphoma and in improving lymphoma progression. Despite the experimental study evidence, our epidemiological study findings do not support the association in NHLs.

Acknowledgements

The authors acknowledge the Manitoba Centre for Health Policy for use of data contained in the Manitoba Population Research Data Repository under project #2015-042 (HIPC#_2015/16-25; HREB # HS18835 (H2015:293); RRIC # 2015-044). The results and conclusions are those of the authors and no official endorsement by the Manitoba Centre for Health Policy, Manitoba Health, or other data providers is intended or should be inferred. Data used in this study are from the Manitoba Population Research Data Repository housed at the Manitoba Centre for Health Policy, University of Manitoba and were derived from data provided by Manitoba Health and CancerCare Manitoba.

References

1. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel L a., et al. Diabetes and cancer: a consensus report. *Diabetes Care* [Internet]. 2010 Jul [cited 2014 Dec 14];33(7):1674–85. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2890380&tool=pmcentrez&rendertype=abstract>
2. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. *Cancer Prev Res* [Internet]. 2010 Nov [cited 2015 May 21];3(11):1451–61. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20947488>
3. Castillo JJ, Mull N, Reagan JL, Nemr S, Mitri J. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: A meta-analysis of observational studies. *Blood*. 2012;119(21):4845–50.
4. Yang W-S, Li H-L, Xu H-L, Yang G, Gao Y-T, Zheng W, et al. Type 2 diabetes and the risk of non-Hodgkin's lymphoma. *Eur J Cancer Prev* [Internet]. 2015;1. Available from: <http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00008469-900000000-99510>
5. Kautzky-Willer A, Thurner S, Klimek P. Use of statins offsets insulin-related cancer risk. *J Intern Med*. 2017;281(2):206–16.
6. Ye X, Mahmud SM. Pharmacological prevention of cancer: Do we have sufficient evidence to support clinical practice? *Oncol Exch*. 2015;14(3):15–20.
7. Boursi B, Mamtani R, Yang Y-X, Weiss BM. Impact of metformin on the progression of MGUS

- to multiple myeloma. Leuk Lymphoma [Internet]. 2017 May 4 [cited 2018 Jan 2];58(5):1265–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27701912>
8. Shi W-Y, Xiao D, Wang L, Dong L-H, Yan Z-X, Shen Z-X, et al. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis [Internet]. Nature Publishing Group; 2012 Mar 1 [cited 2017 Oct 15];3(3):e275. Available from: <http://www.nature.com/doifinder/10.1038/cddis.2012.13>

Table 1 Socio-economic and clinical characteristics of diabetic NHL cases and diabetic cancer-free controls

Characteristics	Case	Control
	(N=878)	(N=4,364)
Male	492 (56.0%)	2,447 (56.1%)
Age group (years)		
40 - 54	58 (6.6%)	282 (6.5%)
55 - 64	175 (19.9%)	872 (20.0%)
65 - 74	272 (31.0%)	1,380 (31.6%)
75+	373 (42.5%)	1,830 (41.9%)
Income quintile		
Q1 (lowest)	183 (20.8%)	1,012 (23.2%)
Q2	214 (24.4%)	905 (20.7%)
Q3	172 (19.6%)	890 (20.4%)
Q4	136 (15.5%)	709 (16.2%)
Q5 (highest)	122 (13.9%)	600 (13.7%)
Unknown	51 (5.8%)	248 (5.7%)
Ever use of medications		
Metformin	455 (51.8%)	2,262 (51.8%)
Insulins	136 (15.5%)	700 (16.0%)
Other oral hypoglycemic drugs	428 (48.7%)	2,116 (48.5%)
Statin	597 (68.0%)	3,020 (69.2%)

Non-statin lipid-lowering drugs	127 (14.5%)	614 (14.1%)
Aspirin	336 (38.3%)	1,657 (38.0%)
Non-aspirin NSAIDs	652 (74.3%)	3,162 (72.5%)
Any NSAIDs	712 (81.1%)	3,505 (80.3%)
Medical conditions		
Chronic cardiovascular disease (excluding hypertension)	69 (7.9%)	279 (6.4%)
Hypertension	72 (8.2%)	366 (8.4%)
Number of physician visits 5 years before index date		
1 - 34	119 (13.6%)	1,056 (24.2%)
35 - 54	227 (25.9%)	1,100 (25.2%)
55 - 84	264 (30.1%)	1,131 (25.9%)
85+	268 (30.5%)	1,077 (24.7%)

Table 2 Adjusted odds ratio (95% confidence interval) of the association between metformin use and NHL incidence risk by subtype

NHL Diagnosis	Number of Cases	Adjusted OR (95% CI)
All NHLs	878	0.93 (0.79-1.10)
CLL/SLL	213	0.85 (0.61-1.18)
DLBCL	177	0.79 (0.55-1.15)
Plasma cell neoplasms	166	0.92 (0.63-1.35)
Follicular lymphoma	111	1.30 (0.82-2.06)
Other NHLs	211	1.01 (0.72-1.42)

Adjusted for sex, age, region of residence, length of registration with the provincial health insurance, length of diagnosed diabetes, income quintile, number of physician visits 5 years before the index date, insulin use, other oral hypoglycemic drug use, statin use, non-statin lipid-lowering drug use, non-aspirin non-steroidal anti-inflammatory drug use and aspirin and derivatives use.

Cancer Epidemiology, Biomarkers & Prevention

AACR American Association
for Cancer Research

Metformin Is Not Associated with Incidence Risk of Non-Hodgkin Lymphomas among Diabetic Patients

Xibiao Ye, Geng Zhang, Christiaan Righolt, et al.

Cancer Epidemiol Biomarkers Prev Published OnlineFirst March 6, 2018.

Updated version	Access the most recent version of this article at: doi: 10.1158/1055-9965.EPI-18-0012
Author Manuscript	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://cebp.aacrjournals.org/content/early/2018/03/06/1055-9965.EPI-18-0012>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.